Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158650 | 0.89 | RET (0.38) | RET | |
| SCHEMBL20158649 | 0.87 | RET (0.40) | RET | |
| SCHEMBL25985026 | 0.86 | RORC (0.35) | RORCRETMEN1MAPK1KMT2A | |
| SCHEMBL12440624 | 0.81 | RORC (0.37) | RORCRETMEN1MAPK1KMT2A | |
| SCHEMBL2087734 | 0.80 | RORC (0.43) | RORCMEN1MAPK1KMT2ACTSK | |
| SCHEMBL20152043 | 0.80 | RORC (0.36) | RORCRETMEN1MAPK1KMT2A | |
| SCHEMBL20975988 | 0.78 | DRD2 (0.40) | RORCRETMEN1MAPK1KMT2A | |
| SCHEMBL21410530 | 0.78 | RORC (0.38) | RORCRETMEN1MAPK1KMT2A | |
| SCHEMBL1994522 | 0.78 | USP2 (0.47) | EPHX2 | |
| SCHEMBL16887631 | 0.78 | CYP4F2 (0.40) | RORCRETMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RORC 440/4885RET 1/4885MEN1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.